Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Megan L. Choy"'
Autor:
Megan L. Choy, Paul A. Marks, Yuanshan Yao, Won-Seok Ham, Gisela Venta-Perez, Ju-Hee Lee, Nathaniel T. Kim, Ronald Breslow, Lang Ngo, Adaickapillai Mahendran
Publikováno v:
Proceedings of the National Academy of Sciences. 110:15704-15709
Development of isoform-selective histone deacetylase (HDAC) inhibitors is important in elucidating the function of individual HDAC enzymes and their potential as therapeutic agents. Among the eleven zinc-dependent HDACs in humans, HDAC6 is structural
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4506681c4570133fe269dfb5623fe08
https://doi.org/10.1073/pnas.1313893110
https://doi.org/10.1073/pnas.1313893110
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
Publikováno v:
Proceedings of the National Academy of Sciences. 108:19629-19634
Histone deacetylase inhibitors (HDACi) are a new group of anticancer drugs with tumor selective toxicity. Normal cells are relatively resistant to HDACi-induced cell death compared with cancer cells. Previously, we found that vorinostat induces DNA b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4543abcfb8faa0f9bb4be18099b258e
https://doi.org/10.1073/pnas.1117544108
https://doi.org/10.1073/pnas.1117544108
Publikováno v:
Proceedings of the National Academy of Sciences. 107:14639-14644
Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high degree of selectivity for killing cancer cells. HDACi induce acetylation of histones and nonhistone proteins, which affect gene expression, cell cycle progression, cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920f4a055b8e34538e8bc02d2ce04288
https://doi.org/10.1073/pnas.1008522107
https://doi.org/10.1073/pnas.1008522107
Publikováno v:
Cancer Letters. 292:215-227
High grade gliomas are aggressive cancers that are not well addressed by current chemotherapies, in large measure because these drugs do not curtail the diffuse invasion of glioma cells into brain tissue surrounding the tumor. Here, we investigate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51db06a466a279cf794d35058fa3b573
https://doi.org/10.1016/j.canlet.2009.12.006
https://doi.org/10.1016/j.canlet.2009.12.006
Publikováno v:
Colloids and Surfaces B: Biointerfaces. 70:114-123
Microcapsules fabricated by layer-by-layer self-assembly have unique physicochemical properties that make them attractive for drug delivery applications. This study chiefly investigated the biocompatibility of one of the most stable types of microcap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0dec321e586db156148f4c5a53aac9
https://doi.org/10.1016/j.colsurfb.2008.12.022
https://doi.org/10.1016/j.colsurfb.2008.12.022
Autor:
Ju-Hee Lee, Adaickapillai Mahendran, Megan L. Choy, Gisela Venta-Perez, Lang Ngo, Yuanshan Yao, Ronald Breslow, Paul A. Marks
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 112(39)
Significance We discovered an improved hydroxamic acid-based small-molecule N-hydroxy-4-[(N(2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide)] that selectively inhibits histone deacetylase 6 catalytic activity in vivo and in vitro. This can have im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e2ec306abf37c39486f8be8523fc0f9
https://pubmed.ncbi.nlm.nih.gov/26483505
https://pubmed.ncbi.nlm.nih.gov/26483505
Publikováno v:
Advances in cancer research. 116
Histone deacetylase (HDAC) inhibitors are a new class of anticancer agents. HDAC inhibitors induce acetylation of histones and nonhistone proteins which are involved in regulation of gene expression and in various cellular pathways including cell gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9fd8367e4cec600782a0510e377ddae1
https://pubmed.ncbi.nlm.nih.gov/23088868
https://pubmed.ncbi.nlm.nih.gov/23088868
Histone deacetylase (HDAC) inhibitors are a new class of anticancer agents. HDAC inhibitors induce acetylation of histones and nonhistone proteins which are involved in regulation of gene expression and in various cellular pathways including cell gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::759a81466e02042e1c0810f7e4a86017
https://doi.org/10.1016/b978-0-12-394387-3.00002-1
https://doi.org/10.1016/b978-0-12-394387-3.00002-1
Autor:
Lang Ngo, Ju-Hee Lee, Yuanshan Yao, Mahendran Adaickapillai, Paul A. Marks, Ronald Breslow, Megan L. Choy, Gisela Venta-Perez
Publikováno v:
Cancer Research. 73:LB-308
Histone deacetylase 6 (HDAC6) is Class IIb deacetylase. HDAC6 is a cytoplasmic protein and has two catalytic domains, an ubiquitin binding domain, and a dynein binding domain. Its substrates include many non-histone proteins such as alpha-tubulin, HS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2da79907790d3e5b420cfb6198e73c0f
https://doi.org/10.1158/1538-7445.am2013-lb-308
https://doi.org/10.1158/1538-7445.am2013-lb-308
Publikováno v:
Molecular Cancer Therapeutics. 10:A206-A206
Histone deacetylase inhibitors (HDACi) are a new class of selective anti-cancer agents that inhibit zinc-dependent histone deacetylases. HDACi in clinical trials have shown anti-cancer activity at well-tolerated doses. The mechanisms of resistance to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::234270bc352aa37c09e3d972271b347a
https://doi.org/10.1158/1535-7163.targ-11-a206
https://doi.org/10.1158/1535-7163.targ-11-a206